Current Value
$1.591 Year Return
Current Value
$1.591 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CORN | -0.15% | $49.57M | 0.2% |
BILZ | 0.25% | $876.85M | 0.14% |
SHY | -0.53% | $24.03B | 0.15% |
NEAR | 0.58% | $3.26B | 0.25% |
SCHO | -0.60% | $10.87B | 0.03% |
KMLM | -0.78% | $188.32M | 0.9% |
IBMN | -0.96% | $446.12M | 0.18% |
TPMN | 1.00% | $31.54M | 0.65% |
IBTH | -1.72% | $1.53B | 0.07% |
GSST | -1.74% | $857.21M | 0.16% |
CTA | -2.07% | $1.05B | 0.76% |
CLOA | 2.12% | $801.79M | 0.2% |
WEAT | -2.13% | $115.83M | 0.28% |
CARY | 2.18% | $347.36M | 0.8% |
SHYD | 2.30% | $318.05M | 0.35% |
UNG | 2.30% | $371.83M | 1.06% |
FXY | -2.54% | $838.61M | 0.4% |
IBTI | 2.68% | $995.39M | 0.07% |
ULST | -2.97% | $637.77M | 0.2% |
VGSH | -2.98% | $22.38B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 41.73% | $4.85B | 0.35% |
IBB | 40.16% | $5.22B | 0.45% |
IWC | 38.23% | $766.88M | 0.6% |
KJUL | 38.08% | $113.35M | 0.79% |
CPRJ | 38.07% | $48.43M | 0.69% |
GNOM | 37.92% | $40.65M | 0.5% |
QVAL | 37.60% | $376.57M | 0.29% |
COWZ | 36.84% | $21.69B | 0.49% |
XHB | 36.48% | $1.26B | 0.35% |
ARKG | 36.45% | $944.78M | 0.75% |
RZV | 36.44% | $200.54M | 0.35% |
IWM | 36.39% | $63.95B | 0.19% |
VTWO | 36.08% | $12.07B | 0.07% |
ERTH | 35.89% | $150.05M | 0.67% |
PBE | 35.80% | $214.12M | 0.58% |
FLCA | 35.74% | $416.90M | 0.09% |
ESML | 35.71% | $1.81B | 0.17% |
SYLD | 35.69% | $985.99M | 0.59% |
GSSC | 35.60% | $538.65M | 0.2% |
PBD | 35.60% | $70.89M | 0.75% |
Yahoo
AC Immune (ACIU) delivered earnings and revenue surprises of 4.55% and 3.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Wednesday reported a loss of $21.2 million in its first quarter. The Lausanne, Switzerland-based company said it had a loss of 21 cents per share. The biopharmaceutical company posted revenue of $1.1 million in the period.
Yahoo
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD)Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025Presentations
Yahoo
Key Insights Significant control over AC Immune by individual investors implies that the general public has more power...
Yahoo
The adaptive and biomarker-based trial comprises two parts and focuses on subjects with early PD.
Yahoo
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EW | -12.03% | $45.10B | -14.68% | 0.00% |
K | -10.79% | $28.49B | +32.17% | 2.77% |
STG | -8.04% | $27.05M | -37.35% | 0.00% |
VHC | -7.36% | $34.69M | +74.89% | 0.00% |
LITB | -7.09% | $21.28M | -72.45% | 0.00% |
FMTO | -5.84% | $45.74M | -99.96% | 0.00% |
CBOE | -5.82% | $22.95B | +20.67% | 1.12% |
CME | -5.14% | $98.74B | +28.80% | 3.84% |
CYCN | -4.03% | $9.37M | +2.39% | 0.00% |
WST | -3.92% | $15.14B | -40.50% | 0.39% |
MNOV | -3.71% | $68.17M | -2.80% | 0.00% |
BULL | -3.57% | $5.67B | +11.22% | 0.00% |
DUK | -3.31% | $90.12B | +12.74% | 3.61% |
PG | -3.28% | $380.78B | -3.25% | 2.51% |
HE | -3.25% | $1.83B | -10.25% | 0.00% |
UGP | -3.18% | $3.30B | -37.47% | 4.06% |
VSTA | -2.20% | $326.82M | +11.64% | 0.00% |
CL | -1.94% | $72.64B | -5.18% | 2.25% |
KMB | -1.83% | $45.57B | +1.99% | 3.58% |
AMED | -1.81% | $3.08B | -1.30% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PSN | 0.00% | $7.29B | -10.84% | 0.00% |
KR | 0.04% | $44.68B | +24.17% | 1.89% |
EXC | -0.04% | $43.84B | +12.45% | 3.59% |
TIMB | -0.05% | $8.38B | +3.30% | 2.99% |
NOC | -0.08% | $67.51B | -0.35% | 1.76% |
ED | -0.15% | $36.75B | +5.26% | 3.28% |
CHD | 0.27% | $23.29B | -11.36% | 1.23% |
WCN | 0.30% | $49.35B | +14.58% | 0.65% |
SO | 0.32% | $96.04B | +10.08% | 3.29% |
UTZ | -0.34% | $1.11B | -29.27% | 1.86% |
FMX | 0.41% | $21.09B | -13.81% | 4.38% |
ADBE | 0.47% | $172.48B | -16.19% | 0.00% |
COR | 0.49% | $55.43B | +28.90% | 0.56% |
CLX | 0.49% | $16.64B | -1.45% | 3.61% |
VSA | 0.52% | $7.04M | -49.24% | 0.00% |
RSG | -0.57% | $76.55B | +30.51% | 0.93% |
HSY | 0.59% | $33.16B | -21.37% | 3.44% |
PRA | 0.62% | $1.19B | +58.17% | 0.00% |
CARV | 0.62% | $7.41M | -22.87% | 0.00% |
INSP | -0.68% | $4.41B | -5.87% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ARCT | 40.82% | $315.68M | -61.84% | 0.00% |
RGNX | 40.37% | $433.39M | -46.03% | 0.00% |
BLD | 39.14% | $8.47B | -26.98% | 0.00% |
ALLE | 37.71% | $12.30B | +13.97% | 1.37% |
SITE | 36.62% | $5.50B | -19.85% | 0.00% |
DEI | 36.56% | $2.51B | +3.96% | 5.06% |
RCKT | 36.43% | $724.54M | -71.26% | 0.00% |
LPX | 36.22% | $6.50B | +4.20% | 1.13% |
BC | 36.05% | $3.42B | -36.07% | 2.42% |
OC | 35.84% | $12.12B | -17.96% | 1.79% |
BXP | 35.51% | $10.60B | +5.23% | 5.86% |
Z | 35.23% | $16.48B | +52.56% | 0.00% |
ALEC | 34.87% | $110.49M | -79.87% | 0.00% |
ZG | 34.84% | $16.23B | +53.09% | 0.00% |
NMR | 34.80% | $17.53B | +0.51% | 2.56% |
CRSR | 34.48% | $903.71M | -23.68% | 0.00% |
HLMN | 34.34% | $1.60B | -15.01% | 0.00% |
BCC | 34.02% | $3.42B | -31.19% | 0.91% |
HNI | 33.90% | $2.22B | +3.22% | 2.74% |
SLG | 33.85% | $4.41B | +9.10% | 5.23% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -26.22% | $361.41M | 1.43% |
VIXY | -25.91% | $109.64M | 0.85% |
TAIL | -21.85% | $140.49M | 0.59% |
IVOL | -12.56% | $353.94M | 1.02% |
KCCA | -9.01% | $97.18M | 0.87% |
GBIL | -8.95% | $6.17B | 0.12% |
BIL | -8.50% | $45.95B | 0.1356% |
USDU | -7.69% | $173.44M | 0.5% |
TBLL | -7.31% | $2.46B | 0.08% |
UUP | -7.00% | $292.27M | 0.77% |
TFLO | -6.52% | $7.06B | 0.15% |
IBTF | -5.76% | $2.12B | 0.07% |
FTSD | -5.59% | $212.46M | 0.25% |
SPTS | -5.26% | $5.76B | 0.03% |
XONE | -4.98% | $603.24M | 0.03% |
IBTG | -4.74% | $1.88B | 0.07% |
JMST | -3.69% | $3.65B | 0.18% |
UTWO | -3.67% | $387.71M | 0.15% |
XHLF | -3.20% | $1.46B | 0.03% |
VGSH | -2.98% | $22.38B | 0.03% |